New weight drug HU6 tested in early human study
NCT ID NCT07170189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called HU6 in 59 overweight adults. The goal was to see how safe the drug is and how the body processes it in tablet and capsule forms. Participants took different doses, and researchers measured drug levels in the blood. This study does not test weight loss directly, but gathers important safety information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
59 people
The number who actually took part.
- Started
-
Oct 2025
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female between 18 and 55 years of age at time of signing the informed consent. * Body mass index (BMI) ≥ 25 kg/m2 at Screening. * Medically stable in the opinion of the investigator based on medical history, physical examination, vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and general observations. Note that Screening abnormalities or findings outside the normal ranges for any clinical assessments that are considered clinically significant by the Investigator (clinical laboratory tests, ECG, vital signs) may be repeated once at the discretion of the Investigator(s), and results that continue to be outside the normal ranges must be judged by the investigator to be not clinically significant and acceptable for study participation. * Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this clinical protocol. Exclusion Criteria: * Current or past clinically significant history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease as determined by the investigator and if deemed necessary, in consultation with the medical monitor, which may impact safety. * History of cancer (except for treated non-melanoma skin cancer) or history of chemotherapy use within 5 years prior to Screening. * Any surgical or medical condition or history that, in the opinion of the investigator, and if deemed necessary, in consultation with the medical monitor, may potentially alter the absorption, metabolism, or excretion of IMP, such as, but not limited to, gastric bypass surgery or gallbladder removal surgery or significant small bowel resections. * Contraindication to IMP or its excipients and/or history of anaphylactic reactions or clinically significant allergic reaction.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Overweight are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
Minneapolis, Minnesota, 55114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vegan diet shield police officers from heart disease?
- Can 10-Minute school break videos get overweight kids moving?
- Weekly shot aims to melt away pounds in obesity fight
- Can meal timing change how well a Weight-Loss pill works?
- Can a new injection help tackle obesity? a trial puts it to the test
- Can an obesity drug weaken birth control? a trial investigates